MetaCap

bioAffinity Technologies (BIAF) vs iSpecimen (ISPC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

bioAffinity Technologies is the larger company by market cap ($3.0 million vs $2.6 million), about 1.1 times the size. bioAffinity Technologies converts more of its revenue into profit, with a net margin of -242.0% versus -543.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BIAF-73.21%ISPC-58.52%
+7%-35%-77%
Oct 7, 20261 yearNov 20, 2026
BIAF-65.08%ISPC-59.62%
+3%-33%-68%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BIAF versus ISPC key metrics
MetricBIAFISPC
Share price$1.65$0.4563
Market cap$3.00M$2.64M
1-day change-10.81%-13.58%
EPS (TTM)$-40.37$-52.98
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$6.16M$1.93M
Revenue growth (YoY)-34.18%-79.24%
Net income (latest FY)$-14.91M$-10.49M
Gross margin—11.18%
Operating margin-171.58%-465.42%
Net margin-241.96%-543.68%
52-week high$80.70$27.44
52-week low$1.63$0.432
Distance from 52-week high-97.96%-98.34%
Average volume3.55M598.66K
Shares outstanding1.82M5.79M
Employees577
SectorHealth CareHealth Care
IndustryBiotechnology: Commercial Physical & Biological ResarchBiotechnology: Commercial Physical & Biological Resarch

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • bioAffinity Technologies is more profitable, keeping -242.0 cents of every revenue dollar as net income versus -543.7 cents for iSpecimen.
  • bioAffinity Technologies grew revenue faster in its latest fiscal year (-34.18% vs -79.24%).

About bioAffinity Technologies

BIAF stock →

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States.

Health Care · Biotechnology: Commercial Physical & Biological Resarch · 57 employees

About iSpecimen

ISPC stock →

iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.

Health Care · Biotechnology: Commercial Physical & Biological Resarch · 7 employees

BIAF vs ISPC FAQ

Which is bigger, bioAffinity Technologies or iSpecimen?

bioAffinity Technologies (BIAF) is larger, with a market capitalization of $3.00M compared with $2.64M for iSpecimen (ISPC).

Are bioAffinity Technologies and iSpecimen in the same industry?

Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.

More comparisons